Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.


Sci. STKE, 24 August 2004
Vol. 2004, Issue 247, p. tw304
[DOI: 10.1126/stke.2472004tw304]

EDITORS' CHOICE

CANCER Stayin' Alive

About 10% of patients with non-small cell lung cancer (NSCLC) experience dramatic tumor regression when treated with gefitinib (Iressa), a recently approved drug that inhibits the kinase activity of the epidermal growth factor receptor (EGFR). Tumors that respond to gefitinib harbor somatic mutations in the EGFR kinase domain. Sordella et al. now show that these mutant EGFRs activate a signaling pathway that keeps the tumor cells alive even when they are treated with agents that induce cell death, such as conventional chemotherapeutic drugs. The authors speculate that NSCLCs expressing the mutant EGFRs may become fully dependent on this cell survival pathway, which could explain, at least in part, their extreme sensitivity to gefitinib.

R. Sordella, D. W. Bell, D. A. Haber, J. Settleman, Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305, 1163-1167 (2004). [Abstract] [Full Text]

Citation: Stayin' Alive. Sci. STKE 2004, tw304 (2004).


To Advertise     Find Products


Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882